Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Amortization of Deferred Charges: 2009-2025

Historic Amortization of Deferred Charges for Cytokinetics (CYTK) over the last 4 years, with Sep 2025 value amounting to $5.6 million.

  • Cytokinetics' Amortization of Deferred Charges rose 62.02% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.0 million, marking a year-over-year increase of 421.80%. This contributed to the annual value of $11.6 million for FY2024, which is 57.46% up from last year.
  • Latest data reveals that Cytokinetics reported Amortization of Deferred Charges of $5.6 million as of Q3 2025, which was up 5.97% from $5.3 million recorded in Q2 2025.
  • Cytokinetics' Amortization of Deferred Charges' 5-year high stood at $7.1 million during Q3 2023, with a 5-year trough of -$13.6 million in Q4 2023.
  • Its 3-year average for Amortization of Deferred Charges is $3.0 million, with a median of $3.5 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Cytokinetics' Amortization of Deferred Charges was 429.85% (2023), while the steepest drop was 1,350.83% (2023).
  • Cytokinetics' Amortization of Deferred Charges (Quarterly) stood at $1.1 million in 2022, then slumped by 1,350.83% to -$13.6 million in 2023, then spiked by 125.95% to $3.5 million in 2024, then surged by 62.02% to $5.6 million in 2025.
  • Its Amortization of Deferred Charges was $5.6 million in Q3 2025, compared to $5.3 million in Q2 2025 and $3.5 million in Q1 2025.